Continuous, low-dose therapy with interferon-α for human immunodeficiency virus (HIV)-related immune thrombocytopenic purpura

Donald W Northfelt, L. D. Kaplan, D. I. Abrams

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A patient with HIV-related immune thrombocytopenic purpura (HIV-ITP) had a rapid rise in platelet count when treated with interferon-α2b, 3 million units three times weekly. There were no significant toxicities with therapy. His platelet count fell to pretreatment levels when therapy was discontinued, then increased again when therapy was reinstituted at 1.5 million units three times weekly. Interferon-α2b, administered continuously at low doses, is well tolerated, effective, and possibly less immunosuppressive than other treatments for HIV-ITP.

Original languageEnglish (US)
Pages (from-to)238-239
Number of pages2
JournalAmerican Journal of Hematology
Volume38
Issue number3
StatePublished - 1991
Externally publishedYes

Fingerprint

Idiopathic Thrombocytopenic Purpura
Interferons
HIV
Platelet Count
Inosine Triphosphate
Therapeutics
Immunosuppressive Agents

Keywords

  • HIV-ITP
  • immunosuppressive
  • platelet count

ASJC Scopus subject areas

  • Hematology

Cite this

Continuous, low-dose therapy with interferon-α for human immunodeficiency virus (HIV)-related immune thrombocytopenic purpura. / Northfelt, Donald W; Kaplan, L. D.; Abrams, D. I.

In: American Journal of Hematology, Vol. 38, No. 3, 1991, p. 238-239.

Research output: Contribution to journalArticle

@article{1f60d6febe4c4f42bea4822a729db8b3,
title = "Continuous, low-dose therapy with interferon-α for human immunodeficiency virus (HIV)-related immune thrombocytopenic purpura",
abstract = "A patient with HIV-related immune thrombocytopenic purpura (HIV-ITP) had a rapid rise in platelet count when treated with interferon-α2b, 3 million units three times weekly. There were no significant toxicities with therapy. His platelet count fell to pretreatment levels when therapy was discontinued, then increased again when therapy was reinstituted at 1.5 million units three times weekly. Interferon-α2b, administered continuously at low doses, is well tolerated, effective, and possibly less immunosuppressive than other treatments for HIV-ITP.",
keywords = "HIV-ITP, immunosuppressive, platelet count",
author = "Northfelt, {Donald W} and Kaplan, {L. D.} and Abrams, {D. I.}",
year = "1991",
language = "English (US)",
volume = "38",
pages = "238--239",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Continuous, low-dose therapy with interferon-α for human immunodeficiency virus (HIV)-related immune thrombocytopenic purpura

AU - Northfelt, Donald W

AU - Kaplan, L. D.

AU - Abrams, D. I.

PY - 1991

Y1 - 1991

N2 - A patient with HIV-related immune thrombocytopenic purpura (HIV-ITP) had a rapid rise in platelet count when treated with interferon-α2b, 3 million units three times weekly. There were no significant toxicities with therapy. His platelet count fell to pretreatment levels when therapy was discontinued, then increased again when therapy was reinstituted at 1.5 million units three times weekly. Interferon-α2b, administered continuously at low doses, is well tolerated, effective, and possibly less immunosuppressive than other treatments for HIV-ITP.

AB - A patient with HIV-related immune thrombocytopenic purpura (HIV-ITP) had a rapid rise in platelet count when treated with interferon-α2b, 3 million units three times weekly. There were no significant toxicities with therapy. His platelet count fell to pretreatment levels when therapy was discontinued, then increased again when therapy was reinstituted at 1.5 million units three times weekly. Interferon-α2b, administered continuously at low doses, is well tolerated, effective, and possibly less immunosuppressive than other treatments for HIV-ITP.

KW - HIV-ITP

KW - immunosuppressive

KW - platelet count

UR - http://www.scopus.com/inward/record.url?scp=0026074893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026074893&partnerID=8YFLogxK

M3 - Article

C2 - 1951326

AN - SCOPUS:0026074893

VL - 38

SP - 238

EP - 239

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -